IE 11 is a very old Browser and it`s not supported on this site
Business report Portfolio at a glance

Portfolio at a glance

Securities as at December 31, 2020

Company

 

Number of securities

 

Change since 31.12.2019

 

Local currency

 

Share price

 

Market value in CHF mn

 

In % of securities

 

In % of shareholders' equity

 

In % of company

Ionis Pharmaceuticals

 

8 220 000

 

225 045

 

USD

 

56.54

 

411.4

 

10.4%

 

10.6%

 

5.9%

Moderna

 

2 854 963

 

(1 962 818)

 

USD

 

104.47

 

264.0

 

6.7%

 

6.8%

 

0.7%

Neurocrine Biosciences

 

3 035 000

 

(193 074)

 

USD

 

95.85

 

257.5

 

6.5%

 

6.6%

 

3.2%

Argenx SE

 

921 332

 

(23 407)

 

USD

 

294.09

 

239.8

 

6.1%

 

6.2%

 

1.9%

Incyte

 

2 900 000

 

(500 000)

 

USD

 

86.98

 

223.3

 

5.6%

 

5.7%

 

1.3%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vertex Pharmaceuticals

 

900 000

 

(340 000)

 

USD

 

236.34

 

188.3

 

4.8%

 

4.8%

 

0.3%

Alexion Pharmaceuticals

 

1 294 428

 

(20 000)

 

USD

 

156.24

 

179.0

 

4.5%

 

4.6%

 

0.6%

Arvinas

 

2 176 903

 

935 000

 

USD

 

84.93

 

163.7

 

4.1%

 

4.2%

 

4.6%

Fate Therapeutics

 

2 030 000

 

2 030 000

 

USD

 

90.93

 

163.4

 

4.1%

 

4.2%

 

2.3%

Agios Pharmaceuticals

 

4 158 902

 

261 948

 

USD

 

43.33

 

159.5

 

4.0%

 

4.1%

 

6.0%

Halozyme Therapeutics

 

3 970 000

 

(3 993 056)

 

USD

 

42.71

 

150.1

 

3.8%

 

3.9%

 

3.0%

Alnylam Pharmaceuticals

 

1 155 000

 

(445 000)

 

USD

 

129.97

 

132.9

 

3.4%

 

3.4%

 

1.0%

Crispr Therapeutics

 

900 884

 

170 422

 

USD

 

153.11

 

122.1

 

3.1%

 

3.1%

 

1.2%

Sage Therapeutics

 

1 540 104

 

260 000

 

USD

 

86.51

 

117.9

 

3.0%

 

3.0%

 

3.0%

Radius Health

 

7 455 714

 

574 029

 

USD

 

17.86

 

117.9

 

3.0%

 

3.0%

 

16.0%

Biogen

 

537 000

 

537 000

 

USD

 

244.86

 

116.4

 

2.9%

 

3.0%

 

0.3%

Myovant Sciences

 

4 757 039

 

(58 070)

 

USD

 

27.62

 

116.3

 

2.9%

 

3.0%

 

5.3%

Intra-Cellular Therapies

 

3 538 419

 

1 238 419

 

USD

 

31.80

 

99.6

 

2.5%

 

2.6%

 

4.4%

Macrogenics

 

4 815 564

 

296 405

 

USD

 

22.86

 

97.4

 

2.5%

 

2.5%

 

8.4%

Scholar Rock Holding

 

2 255 651

 

(378 815)

 

USD

 

48.53

 

96.9

 

2.5%

 

2.5%

 

6.7%

Esperion Therapeutics

 

3 947 964

 

220 000

 

USD

 

26.00

 

90.9

 

2.3%

 

2.3%

 

14.2%

Generation Bio Co.

 

2 333 180

 

2 333 180

 

USD

 

28.35

 

58.6

 

1.5%

 

1.5%

 

5.0%

Molecular Templates

 

6 380 331

 

5 084 644

 

USD

 

9.39

 

53.0

 

1.3%

 

1.4%

 

12.8%

Relay Therapeutics

 

1 409 357

 

1 409 357

 

USD

 

41.56

 

51.8

 

1.3%

 

1.3%

 

1.6%

Exelixis

 

2 835 000

 

 

USD

 

20.07

 

50.4

 

1.3%

 

1.3%

 

0.9%

Mersana Therapeutics

 

1 885 000

 

1 885 000

 

USD

 

26.61

 

44.4

 

1.1%

 

1.1%

 

2.8%

Nektar Therapeutics

 

2 620 676

 

 

USD

 

17.00

 

39.4

 

1.0%

 

1.0%

 

1.5%

Black Diamond Therapeutics

 

1 390 000

 

1 390 000

 

USD

 

32.05

 

39.4

 

1.0%

 

1.0%

 

3.9%

Beam Therapeutics

 

396 821

 

396 821

 

USD

 

81.64

 

28.7

 

0.7%

 

0.7%

 

0.7%

Kezar Life Sciences

 

4 533 148

 

2 982 479

 

USD

 

5.22

 

20.9

 

0.5%

 

0.5%

 

9.8%

Wave Life Sciences

 

2 602 858

 

200 000

 

USD

 

7.87

 

18.1

 

0.5%

 

0.5%

 

5.3%

Homology Medicines

 

1 737 122

 

125 000

 

USD

 

11.29

 

17.4

 

0.4%

 

0.4%

 

3.8%

Voyager Therapeutics

 

2 680 283

 

 

USD

 

7.15

 

17.0

 

0.4%

 

0.4%

 

7.2%

Cidara Therapeutics

 

2 822 495

 

527 223

 

USD

 

2.00

 

5.0

 

0.1%

 

0.1%

 

6.4%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Alder Biopharmaceuticals – Contingent Value Right

 

2 766 008

 

 

USD

 

0.88

 

2.2

 

0.1%

 

0.1%

 

 

Bristol-Myers Squibb – Contingent Value Right

 

800 000

 

 

USD

 

0.00

 

0.0

 

0.0%

 

0.0%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total securities

 

 

 

 

 

 

 

 

 

3 954.7

 

100.0%

 

101.7%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other assets

 

 

 

 

 

 

 

 

 

8.4

 

 

 

0.2%

 

 

Other payables

 

 

 

 

 

 

 

 

 

(75.6)

 

 

 

(1.9%)

 

 

Net asset value

 

 

 

 

 

 

 

 

 

3 887.5

 

 

 

100.0%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BB Biotech registered shares 1)

 

114 662

 

114 662

 

 

 

 

 

8.5

 

 

 

 

 

0.2%

1 Correspond to the total of all own shares held including the second trading line

Exchange rate as at 31.12.2020: USD/CHF: 0.8852

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience.Use of cookies & disclaimer